Dantrolene and Urinary Effects
Yes, dantrolene has a documented connection to urinary effects, but the relationship is complex and bidirectional—it can cause both urinary retention (decreased urination) and, in specific contexts, may affect bladder contractility, though increased urination is not a commonly reported adverse effect.
Direct Urinary Adverse Effects
The FDA drug label for dantrolene does not list increased urination or urinary spasms as recognized adverse effects 1. However, there is a documented case of dantrolene-induced urinary retention with detrusor acontractility (bladder paralysis) that completely resolved when the dantrolene dose was reduced 2. This case involved a patient receiving 250 mg daily of oral dantrolene for spasticity following traumatic brain injury.
Mechanism and Clinical Context
Dantrolene's primary mechanism is skeletal muscle relaxation through inhibition of calcium release from the sarcoplasmic reticulum 1. Its effects on smooth muscle, including bladder detrusor muscle, remain controversial:
- In canine studies, dantrolene showed no statistically significant inhibitory effect on acetylcholine-induced detrusor contractions 3
- In guinea pig studies, dantrolene reversibly decreased detrusor responses to acetylcholine and histamine 4
- In clinical practice, dantrolene has been used to treat external urinary sphincter hypertonicity in spinal cord injury patients, with 8 of 15 patients showing benefit through decreased skeletal muscle tone 5
Paradoxical Use in Bladder Disorders
Interestingly, dantrolene has been reported as beneficial for detrusor overactivity when combined with antimuscarinics in a patient with cerebral palsy, suggesting it may help reduce bladder spasms in specific neurogenic contexts 6. This represents the opposite effect from urinary retention.
Clinical Implications
The key distinction is:
- Urinary retention/acontractility can occur as an adverse effect, particularly at higher doses (≥250 mg/day)
- Reduced urinary spasms may occur therapeutically when treating external sphincter hypertonicity in neurogenic bladder conditions
- Increased urination is not a recognized adverse effect of dantrolene
Monitoring Recommendations
When using dantrolene, particularly at doses above 200 mg daily:
- Monitor for urinary retention and measure post-void residual volumes if symptoms develop
- Consider dose reduction if bladder dysfunction emerges
- Be aware that liver function monitoring is more critical than urinary monitoring, as hepatotoxicity is a more serious concern 1, 6
If a patient reports increased urination while on dantrolene, investigate alternative causes, as this is not a characteristic effect of the medication. Urinary retention or decreased bladder contractility are the documented urinary effects.